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KEY POINTS 
A gain-of-function variant in DIAPH1 is the basis of a new human syndromic 
disorder of macrothrombocytopenia and sensorineural hearing loss 
  
Our observations of altered megakaryopoiesis and platelet cytoskeletal 
regulation highlight a critical role for DIAPH1 in platelet formation 
 
ABSTRACT  
Macrothrombocytopenia (MTP) is a heterogeneous group of disorders characterised 
by enlarged and reduced numbers of circulating platelets, sometimes resulting in 
abnormal bleeding. In most MTP, this phenotype arises because of altered 
regulation of platelet formation from megakaryocytes (MK). We report the 
identification of DIAPH1, which encodes the Rho-effector diaphanous-related formin 
1 (DIAPH1), as a candidate gene for MTP using exome sequencing, ontological 
phenotyping and similarity regression. We describe two unrelated pedigrees with 
MTP and sensorineural hearing loss that segregate with a DIAPH1 p.R1213* variant 
predicting partial truncation of the DIAPH1 diaphanous autoregulatory domain. The 
R1213* variant was associated with reduced proplatelet formation from cultured MK, 
cell clustering and abnormal cortical filamentous actin. Similarly, in platelets there 
was increased filamentous actin and stable microtubules, indicating constitutive 
activation of DIAPH1. Over-expression of DIAPH1 R1213* in cells reproduced the 
cytoskeletal alterations found in platelets. Our description of a novel syndromic 
disorder of platelet formation and hearing loss extends the repertoire of 
characterised human MTP and provides new insights into the autoregulation of 
DIAPH1 activity. 
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INTRODUCTION 
Platelet formation by megakaryocytes (MKs) requires an ordered sequence of 
differentiation steps from haematopoietic stem cells followed by MK maturation, during 
which repeated rounds of DNA replication without cell division usually result in very 
large MKs with a single nucleus and DNA contents up to 128N. This process enables 
the accumulation of platelet-specific granules and a demarcation membrane system 
that will later contribute to the platelet cytoplasmic contents and surface membrane.1, 2 
Platelets are generated from mature MKs by the protrusion of cytoplasmic extensions 
termed proplatelets into bone marrow sinusoids, where final platelet sizing and 
shaping occurs.3 Platelet formation strongly depends on microtubules, which enable 
proplatelet elongation and transport of organelles from the MK cytoplasm, 1 and actin-
dependent processes, which mediate the branching of elongating proplatelets, thereby 
determining the number of available proplatelet tips to form platelets.4 
 
Altered regulation of platelet formation is a feature of several human hematopoietic 
disorders, including macrothrombocytopenia (MTP) in which there are enlarged and 
reduced numbers of circulating platelets, sometimes resulting in abnormal bleeding.5, 6 
MTP has been associated with pathogenic variants in genes that regulate MK 
maturation (GATA1, GFI1B and NBEAL2) or which encode platelet surface proteins 
(GP1BA, GP1BB, GP9, ITGA2B and ITGB3; reviewed in 5). However, a prevalent sub-
group of MTP arise from variants in ACTN1,7 FLNA,8 MYH9,9, 10 TUBB1,11 and 
PRKACG12 which encode MK cytoskeletal proteins or interactors. It has been 
proposed that the platelet phenotype associated with some MYH9,13, 14 ACTN1,7 and 
TUBB115 variants results from aberrant cytoskeletal rearrangements during proplatelet 
formation, leading to altered platelet production. Cytoskeletal dysfunction may also 
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underlie associated phenotypes such as hearing loss, cataract and glomerulopathy 
with some MYH9 variants 10, 16 and periventricular nodular heterotopia and 
otopalatodigital syndromes with some FLNA variants.8  
 
Here we extend the repertoire of MTP by reporting the discovery of a new dominant 
syndromic disorder of platelet formation. We show that MTP was associated with 
sensorineural hearing loss in two unrelated pedigrees and that this phenotype 
segregates with the same chain-truncating variant in DIAPH1, which encodes the 
cytoskeletal regulator and Rho-effector, diaphanous-related formin 1 (DIAPH1, 
mDia1), identified previously as a regulator of megakaryocytopoiesis in vitro. 17 
 
METHODS 
Recruitment of cases and genetic analysis. 
The cases were enrolled to the BRIDGE-BPD study (UK REC10/H0304/66) or French 
‘Network on the inherited diseases of platelet function and platelet 
production’ (INSERM RBM 04-14) after providing informed written consent. Control 
groups comprised other cases with bleeding or platelet disorders (BPD) of unknown 
genetic basis or with unrelated rare disorders enrolled to the NIHR BioResource-Rare 
Diseases study (UK REC 13/EE/0325). Data collection, human phenotype ontology 
(HPO) coding and high throughput sequencing were performed as previously 
reported.18 Splice site, frameshift, stop-gain/loss or start-loss variants were analysed 
further if they were less frequent than 1 in 10,000 in the Exome Aggregation 
Consortium (ExAC) database and 1 in 100 in our in-house database. Candidate genes 
for BPD were identified by phenotype similarity regression19 to allow for the high 
degree of phenotypic and genetic heterogeneity amongst the BPD cases. 
6 
 
Platelet imaging 
Fixed peripheral blood smears were stained with May-Grünwald-Giemsa stain 
(MGG). Transmission electron microscopy was performed on platelets fixed with 
2.5% glutaraldehyde. Platelet diameters and surface areas were measured in a 
minimum of 99 sections for each case using ImageJ as described previously.8 
 
Megakaryocyte colony culture and analysis 
CD34+ hematopoietic stem cells (HSCs) were isolated from peripheral blood by 
magnetic cell sorting and differentiated into MK as described previously in plate and 
liquid cultures.20, 21 MK-colony forming units (MK-CFU) and MK were visualised by 
light or confocal microscopy after staining with MMG, phalloidin or anti-CD61 
antibodies. Proplatelet formation (PPF) in liquid MK cultures was determined by light 
microscopy and ploidy by flow cytometry as described previously.21 
 
DIAPH1 expression in cell lines 
The DIAPH1-R1213* cDNA was generated by site directed mutagenesis of the full-
length wild-type DIAPH1 cDNA and cloned into the pCMV6-Fc-S (Origene, Rockville, 
MD) mammalian expression vector, before transient transfection into human 
embryonic kidney (HEK293FT) or adenocarcinomic human alveolar basal epithelial 
(A549) cells, cultured using standard conditions. 
 
Western blotting and immunofluorescence microscopy  
Denatured washed platelet or transfected HEK293FT cell lysates were separated by 
SDS-PAGE and blotted onto PVDF membranes. The membranes were probed with 
primary antibodies recognising DIAPH1, DIAPH3, DIAPH2, GAPDH, β-tubulin, 
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Tyrosinated tubulin (Tyr-tubulin), detyrosinated tubulin (Glu-tubulin) and acetylated 
tubulin (ac-tubulin).  
 
For confocal microscopy, transfected A549 cells or platelets applied to fibrinogen-
coated coverslips were fixed and probed with antibodies recognising tubulin or 
DIAPH1 as described above. Filamentous actin was stained using phalloidin-
Atto647N. Where indicated, platelets were pre-incubated with 10 µM colchicine. 
Platelets and cells were visualised by confocal microscopy as reported previously.22 
 
Microtubule sedimentation and cold-induced disassembly 
Polymerised and soluble microtubule fractions were prepared from lysates of resting 
or colchicine-treated (10 µM) platelets and from resting or SMIFH2-treated (25 µM) 
transfected HEK293FT cells by centrifugation for 30 min at 100,000 g and 37°C. 
Microtubule fractions were visualised by Western blot. Microtubules were 
depolymerised by incubation of platelets at 4°C. Reassembly was allowed by 
subsequent rewarming at 37°C as previously reported. 22-24 
 
Detailed methods and uncropped images of Western blots are provided in 
Supplementary material. 
 
RESULTS 
Selection of DIAPH1 as a candidate gene for MTP  
We identified DIAPH1 as a novel candidate gene for MTP by analysing data from 702 
index cases with bleeding or platelet disorders of unknown genetic basis recruited to 
BRIDGE-BPD study of the NIHR Bioresource-Rare Diseases. Control data were 
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analysed from 3,453 cases with unrelated rare disorders or unaffected pedigree 
members recruited to other branches of the NIHR Bioresource-Rare Diseases.  
 
There were 1,073 genes for which at least two BPD cases carried a rare variant 
predicted to have a high impact on gene translation. After phenotype similarity 
regression analysis of the genes in this group, DIAPH1 had the highest probability for 
the model specifying a statistical association between phenotype and genotype for 
which thrombocytopenia was inferred (mean (γ)=0.81; Fig. 1a) The inferred 
characteristic phenotype for DIAPH1 primarily comprised the HPO terms 
“Sensorineural hearing impairment” and “Abnormality of blood and blood-forming 
tissues”, with the latter driven by the terms “Thrombocytopenia” and “Abnormal 
bleeding” (Fig. 1b).  
 
Two index cases from different pedigrees in the BRIDGE-BPD collection (Bordeaux 
case 17 and Bristol case 21; Fig. 1c) harboured the same high-impact variant in 
DIAPH1. This was a heterozygous c.3637C>T transition, annotated relative to the 
DIAPH1 isoform ENST00000398557, which encodes the CCDS-annotated DIAPH1 
protein (UNIPROT O60610). This predicted substitution of the conserved (PhyloP 
p=5.25 × 10-4) arginine at amino acid position 1213 with a premature stop codon 
(R1213*; Fig. 2). This variant was not observed in any of the 61,486 exomes in the 
ExAC database nor in the remaining 4,151 exomes sequenced in-house. Sanger 
sequencing showed that the R1213* variant was present in six further pedigree 
members with both MTP and sensorineural hearing loss but was absent in three 
asymptomatic pedigree members, indicating segregation with the DIAPH1 genotype 
(p=3.66 × 10-4, conditional on the genotypes of the index cases; Fig. 1c). We found no 
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other rare variants shared by the index cases within 10 Mb around DIAPH1. The 
sequencing data provided no evidence that these cases were closely related at 
genome-wide level or more locally within the DIAPH1-containing chromosome 5 
(Supplementary Fig. 1). 
 
The R1213* variant predicts DIAPH1 protein truncation.  
DIAPH1 is a homodimeric formin family protein that promotes actin assembly and 
regulates microtubule stability through a formin homology (FH) 1 domain which 
contains binding sites for profilin, and an FH2 domain which promotes nucleation 
and elongation of actin filaments and possibly microtubule interactions.25-27 DIAPH1 
is regulated by a diaphanous auto-regulatory domain (DAD) near the carboxyl 
terminus, which inhibits DIAPH1 activity through an interaction with the diaphanous 
inhibitory domain (DID) near the amino terminus (Fig. 2). Auto-inhibition is normally 
released by competitive binding of activated Rho GTPases, enabling cytoskeletal 
remodelling. 28,29 The inhibitory DAD-DID interaction is mediated by ‘core’ MDxLLExL 
and ‘basic’ RRKR motifs in the DAD (Fig. 2) that bind cognate DID sequences.30  
 
Reverse-transcriptase (RT) PCR and PCR amplification of the R1213 region and 
subsequent restriction endonuclease digestion proved the presence of both wild type 
and R1213* DIAPH1 mRNA transcripts in platelets from cases 10 and 16 
(Supplementary Fig. 2). The premature stop codon created by the R1213* variant 
occurs at position 1 of the RRKR motif (residues 1213-1216), but is closer to the 
DIAPH1 carboxyl terminus than the MDxLLExL motif (residues 1199-1206). 
Therefore, the predicted consequence of the R1213* variant is expression of 
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DIAPH1 protein with a truncation within the DAD resulting in loss of the RRKR motif, 
but not the MDxLLExL motif (Fig. 2). 
 
DIAPH1 R1213* is associated with syndromic MTP and hearing loss.  
All eight genotyped R1213* cases had thrombocytopenia (baseline automated platelet 
counts 63-147 x109 L-1) and enlarged platelets (mean platelet volume (MPV) 11.2-14.1 
fL), confirmed by light microscopy (Fig 3a. and Table 1) and by morphometric 
analysis of platelet electron micrographs (table 2). The platelet count ranges in the 
male and female cases corresponded to the 0.15-2.81th percentiles and 0.08-0.38th 
percentiles respectively of a sex-stratified population of 443,142 UK BioBank 
volunteers. For MPV, the corresponding percentiles were 99.81-99.83 and 94.14-
99.92 (Supplementary Fig.3). Asymptomatic mild neutropenia was observed on at 
least one occasion in six cases (range of neutrophil counts 0.62-4.34 x109 L-1), but 
varied within the cases at different times (Table 1). The erythroid lineage was normal 
in all the cases. Platelets from three tested cases showed normal aggregation with 
ADP (2.5-10 µM), collagen (2 µg mL-1), arachidonic acid (0.5 mg mL-1), TRAP-14mer 
(50 µM) and ristocetin (0.5-1-5 mg mL-1). ADP and TRAP-stimulated dense granule 
secretion determined by measuring ATP release (cases 10, 16, 17 and 21) and α-
granule secretion (cases 10 and 16) determined by measuring P-selectin surface 
exposure, were unchanged compared to controls. Platelet surface expression of αIIbβ3 
integrin and glycoprotein Ib-IX-V (cases 10, 16 and 17) was slightly increased 
compared with controls, consistent with the increased platelet size. Electron 
microscopy (cases 10, 16, 17 and 21) showed that the enlarged platelets were 
typically round, although occasionally highly elongated. There were also abnormal 
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vacuoles, membrane complexes and abnormally distributed α-granules, some of 
which were unusually large (Fig. 3b).  
 
Abnormal bleeding symptoms comprised menorrhagia and mild subcutaneous 
bleeding in case 17 and a post-partum bleed in case 21, but were absent in the other 
cases. The sensorineural hearing loss that segregated with MTP was detected either 
at birth or in the first decade of life but progressed rapidly to a severe defect requiring 
bilateral hearing aids in all eight cases.  
 
Abnormal maturation of DIAPH1 R1213* MK.  
Assessment of MK proliferation, differentiation and proplatelet formation of CD34+ 
stem cell-derived MKs from case 21 and controls on two separate occasions, 
revealed similar numbers of MK colony forming units (CFU-MK) at day 12 of culture 
(Fig. 4a). However, the MK colonies from case 21 had a higher cell density 
compared to controls (Fig. 4b and Supplementary Fig. 4). Suspension cultures 
from case 21 showed a pronounced defect in PPF compared to controls in two 
independent experiments (Fig. 4c and 4d). In addition, we found numerous MK 
clusters containing small and large MKs (Fig. 4d and Supplementary Fig. 5) in 
cultures from case 21, that were not present in control cultures, which hampered 
analysis of MK ploidy by flow cytometry (Supplementary Fig. 6). 
 
Confocal microscopy of control MKs on day 12 of culture showed a partial co-
localization of CD61 and filamentous actin (F-actin), which was not observed in MKs 
from case 21 (Fig. 4e). There was also aberrant architecture of the cortical F-actin 
cytoskeleton in MKs from case 21 and small filopodia-like protrusions and F-actin 
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positive junctions at the contact zones of clustered MKs (Fig. 4e). This is in line with 
previous studies where DIAPH1 was shown to regulate adherens junctions via the 
actin network.31, 32 
 
The R1213* variant is associated with altered DIAPH expression in platelets. 
We next investigated the effect of the R1213* variant on DIAPH1 expression in 
platelets by performing Western blots using an antibody recognising the DIAPH1 
amino-terminus. In platelets from cases 10, 16, and 21, the 155 kDa band, 
corresponding to full length DIAPH1 protein, was decreased in intensity compared 
with controls, while a band of approximately 80 kDa was more intense (Fig. 5a; 
Supplementary Fig. 7). The 80 kDa band did not correspond to any DIAPH1 
transcripts listed in Ensembl, but following immunoprecipitation and mass-
spectrometry, was found to contain peptide sequences with 57% coverage across 
the full length of the DIAPH1 protein sequence (Supplementary information). 
Moreover, this band was also immunoreactive with antibodies recognising the 
DIAPH1 carboxyl terminus, suggesting that it resulted from limited proteolysis of 
DIAPH1 in platelets. Since DIAPH1 expressed from the R1213* variant allele is 
predicted to have only a 60 amino acid truncation, it was not possible to resolve the 
relative contribution of the variant DIAPH1 to either of the immunoreactive bands.  
 
Western blots generated from platelets from the R1213* cases also showed 
increased DIAPH2 and DIAPH3 expression compared with controls (Fig. 5a). 
Expression of DIAPH2 and DIAPH3 has previously been observed to decrease 
during MK maturation,17 which we confirmed by RNA-seq analysis (Supplementary 
Fig. 8). Therefore, our observations in the R1213* cases are consistent with platelet 
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formation from MK with deregulated maturation and support the previous 
observations in MK from bone marrow and culture (Fig. 4a and 4b).17 
 
DIAPH1 R1213* and altered platelet cytoskeleton.  
Using confocal microscopy, we found that DIAPH1 was localised to the peripheral 
marginal band in resting platelets from controls, but was distributed throughout the 
cytoplasm of platelets from the R1213* cases 10 and 16 (Fig. 5b). There was also 
increased F-actin and α-tubulin staining, and aberrant organisation of microtubules 
compared with controls (Fig. 5b). Electron microscopy confirmed microtubule 
disorganisation (Fig. 5c) and quantification by manual counting revealed 
approximately 2.6 fold more microtubule coils in platelets from the R1213* cases 
compared to controls (Fig. 5d). Incubation of platelets from controls at 4°C caused 
disassembly of microtubules, which then reassembled to the marginal band after 
rewarming to 37°C, as previously reported.22-24 In contrast, cold incubation or 
rewarming did not grossly affect the microtubules in platelets from the R1213* cases 
(Fig. 6a), suggesting that the increased microtubule content resulted from increased 
microtubule stability. 
 
The formation of stable microtubules is associated with post-translational 
detyrosination (Glu-tub) and acetylation (ac-tub) of α-tubulin, whereas dynamic 
microtubules are characterised by unmodified tyrosinated α-tubulin (Tyr-tub).33,34 
Following treatment with colchicine or cold incubation to destabilise microtubules, 
platelets from the R1213* cases 10 and 16 showed a higher content of stable 
detyrosinated and acetylated microtubules, compared with controls (Fig. 6b; 
Supplementary Fig. 9 and 10). During spreading on fibrinogen, platelets from the 
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R1213* cases maintained detyrosinated and acetylated microtubules, whereas 
these modifications were not detected in controls (Fig. 6c). Platelets from the 
R1213* cases also displayed an increased content and aberrant organization of F-
actin, particularly at the platelet cortex where there was increased formation of small 
filopods (Fig. 6c). Fractionation of the tubulin cytoskeleton by ultracentrifugation 
revealed higher ac-tub/Tyr-tub and Glu-tub/Tyr-tub band density ratios in the 
R1213* cases compared with controls, particularly in the polymerised (pellet) 
microtubule fraction, confirming a higher content of stable microtubules (Fig. 6d and 
Supplementary Fig. 10).  
 
DIAPH1 R1213* alters cytoskeletal organisation in cell lines.  
In HEK293FT cells transfected with wild type (DIAPH1 WT) or variant (DIAPH1 
R1213*) expression constructs, Western blots confirmed overexpression of both 
DIAPH1 WT and DIAPH1 R1213* proteins. However, in contrast to platelets from 
the R1213* cases, expression of DIAPH2 or DIAPH3 was not increased, allowing us 
to study the effect of the truncated R1213* DIAPH1 variant in isolation (Fig. 7a). 
Transfection of the human adenocarcinoma lung (A549) epithelial cell line with both 
expression constructs increased the prevalence of F-actin and acetylated and 
detyrosinated microtubules compared with adjacent untransfected cells. This effect 
was more pronounced in DIAPH1 R1213* (Fig. 7b and 7c) than in DIAPH1 WT cells 
(Supplementary Fig. 11). 
 
Western blot analysis of microtubule fractions showed that the DIAPH1 R1213* 
transfected HEK293FT cells had a higher content of acetylated and detyrosinated 
microtubules in the polymerised tubulin fraction, compared with DIAPH1 WT or 
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mock-transfected controls (Fig. 7e and Supplementary Fig. 11), thereby 
reproducing the cytoskeletal alterations found in platelets from the cases. Incubation 
of the cells with the small molecule FH2-domain inhibitor SMIFH2 did not influence 
expression of DIAPH1, 2 or 3 (Fig. 7a) and did not prevent stabilisation of 
microtubules by DIAPH1 R1213* (Fig. 7d and 7e). However, SMIFH2 did prevent 
the increase in F-actin content in cells overexpressing DIAPH1 R1213* (Fig. 7d) 
confirming that the DIAPH1 FH2 domain is critical for the F-actin polymerisation.  
 
DISCUSSION 
We have identified DIAPH1 as a novel candidate gene for dominant MTP and 
sensorineural hearing loss by analysis of the largest ever assembled collection of 
cases with previously uncharacterised BPD. Essential to this discovery was the 
annotation of the characteristics of the cases with HPO terms for haematological 
features and phenotypes in other organ systems, and then statistical analysis to 
identify similarities in HPO terms between cases. We have previously shown that 
cluster analysis of HPO terms within a large BPD case collection enabled identification 
of causal variants in ACTN1 and MYH9 that have previously been associated with 
MTP.7, 9 However, the statistical evidence supporting DIAPH1 as a candidate gene 
could only be obtained by applying a novel similarity regression method to the 
phenotype and genotype data.19 Specifically, similarity regression revealed a hitherto 
unidentified association between a characteristic phenotype that was ontologically 
similar for two unrelated index cases and the shared presence of a high impact variant 
in DIAPH1. We also showed that the high impact variant in DIAPH1 was the same 
premature stop variant R1213* in both index cases and that this segregated with MTP 
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and sensorineural hearing loss in a further six pedigree members, thereby confirming 
linkage with R1213*. 
 
It is noteworthy that DIAPH1 has been identified previously as the candidate gene for 
non-syndromic sensorineural deafness type DFNA1 (ORPHA90635) in a single 
characterised pedigree, in which hearing loss typically developed later in childhood 
than in the R1213* cases.35, 36 The causal variant for DFNA1 caused aberrant splicing 
of DIAPH1 in lymphocyte cDNA that predicted expression of DIAPH1 with an 
abnormal carboxyl terminus sequence from glutamine 1220, and chain truncation after 
a further 21 amino acids.35 No platelet count or volume data are reported for the 
DFNA1 pedigree preventing a direct comparison with the R1213* pedigrees reported 
here. However, an important difference is that the DFNA1 variant disrupts only the two 
final residues in the DIAPH1 DAD domain (1194-1222 in UNIPROT O60610). In 
contrast to R1213*, this does not result in loss of the autoregulatory basic RRKR 
motif. Absent expression of DIAPH1 resulting from a homozygous stop-gain variant at 
codon 778 has been associated previously with a distinct disorder of short stature, 
microcephaly and visual impairment without reported hearing or haematological 
phenotypes.37 
 
MTP and hearing loss may also co-segregate in MYH9-related disorder (MYH9-RD; 
ORPHA182050) in which abnormal expression of non-muscle myosin heavy chain IIa 
alters myosin-dependent organelle distribution and F-actin organisation, thereby 
disrupting MK proplatelet formation.13, 14 Aberrant cytoskeletal organisation in inner 
ear stereocilia has been proposed as a mechanism for hearing loss in MYH9-RD,16 
and may contribute to this phenotype in the DIAPH1 R1213* cases. However, there 
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are also several characteristics of the DIAPH1 R1213* cases that are absent in 
MYH9-RD. For example, platelets in the R1213* cases were elongated or round, 
moderately enlarged and contained few membrane complexes, whereas in MYH9-RD, 
platelets are highly enlarged and contain abundant membrane complexes. Hearing 
loss was early onset and severe in the R1213* cases but develops in only 35% of 
MYH9-RD cases, typically after 10 years of age.10 Cataract and nephropathy are 
reported in 5% and 21% of MYH9-RD cases respectively,10 but were absent in the 
R1213* cases. 
 
DIAPH1 is a conserved member of the formin protein family, which mediate Rho-
GTPase dependent assembly of F-actin and microtubule regulation during 
cytoskeletal remodelling in cytokinesis, organelle trafficking and filopodia formation. 
Several mammalian formins mediate cell differentiation and adhesive events 
required for haematopoiesis.25, 38 However, a critical negative regulatory role for 
DIAPH1 is indicated by observations that targeted knockout of the murine DIAPH1 
ortholog Drf1 resulted in hyperproliferative myelodysplasia.39, 40 Consistent with this, 
DIAPH1 knockdown in cultured human MK, resulted in increased proplatelet 
formation.17 In contrast, overexpression of a constitutively active DIAPH1 in which 
both the DID and DAD were deleted by artificial mutagenesis (mDiaΔN3), reduced 
proplatelet formation in cultured human MK. 17 We also observed reduced proplatelet 
formation in CD34+ cell-derived MK from R1213* case 21, suggesting that this 
variant may also result in constitutive activation of DIAPH1. The MK culture 
experiments also suggested that the R1213* variant was associated with enhanced 
MK proliferation as an increased number of cells was present in the separate CFU-
MK colonies from case 21. As a consequence of the increased cell density in the 
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CFU-MK colonies, we were unable to confirm this by counting the total number of 
single MKs. However, ploidy analysis of suspension cultures revealed no obvious 
differences in MK endomitosis as both large and small MKs were present in cultures 
from case 21. Further studies are required to evaluate the possibility of a 
hyperproliferative effect of early MKs due to the R1213* variant.   
 
The hypothesis that the R1213* variant results in constitutively active DIAPH1 is also 
supported by the prediction that R1213* results in partial truncation of the 
autoregulatory DIAPH1 DAD. Mutagenesis of the DAD has been shown previously to 
increase the formation of stable microtubule networks and F-actin bundles in cell 
models,41, 42 consistent with loss of the inhibitory DID-interaction. This interaction is 
mediated in part by a DAD core MDxLLExL motif, which is unaffected by the R1213* 
variant. However, there is also an inhibitory interaction between the DAD basic RRKR 
motif that is absent in the R1213* variant, and a cognate acidic groove in the DID.30 
This second site of DID-DAD interaction is necessary for complete auto-regulation of 
DIAPH1 since selective mutagenesis of the basic RRKR motif also conferred 
constitutive activity to DIAPH1 orthologs, resulting in abnormal F-actin polymerisation 
and altered cell architecture.42, 43  
 
We provided experimental support for constitutive activation of DIAPH1 by showing 
disorganisation of actin filaments and increased stability and content of microtubules 
in platelets from the R1213* cases (Fig. 6a-d). Overexpression of DIAPH1 R1213* 
also resulted in increased assembly of actin filaments and stabilisation of microtubules 
in cell lines (Fig. 7), thereby reproducing the cytoskeletal alterations observed in 
platelets from the R1213* cases. These effects on cytoskeletal organisation may 
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account directly for the reduced proplatelet formation from MKs derived from the 
cases (Fig. 4c and 4d), since highly regulated microtubule and F-actin dynamics are 
necessary for proplatelet extension and branching.4, 44, 45 It is noteworthy that 
overexpression of the constitutively active DIAPH1 mDiaΔN3 which reduced 
proplatelet formation in cultured human MK,  was shown previously to increase 
polymerisation of filamentous actin, similar to that observed with the R1213* variant. 
However, in MKs overexpressing mDiaΔN3, microtubule stability was reduced 
showing that the cytoskeletal alterations do not completely reproduce those 
associated with the R1213* variant.17 One possible explanation for this difference is 
that in contrast to R1213*, the mDiaΔN3 model additionally carries an N-terminal 
deletion including the Rho GTPase-binding domain of DIAPH1, potentially causing a 
different effect of DIAPH1 regulation.17, 42  
 
The gain-of-function R1213* DIAPH1 variant represents a new human dominant 
syndromic disorder of MTP and sensorineural hearing loss that is clinically distinct 
from other MTP disorders and has different characteristics than DIAPH1 gene 
deletion models. The platelet phenotype of the R1213* variant cases highlights the 
impact of abnormal regulation of DIAPH1 on cytoskeletal organisation during platelet 
production. 
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FIGURE LEGENDS 
Figure 1: DIAPH1 is a candidate gene for macrothrombocytopenia and hearing 
loss (a) Each BPD index case was coded using Human Phenotype Ontology (HPO) 
terms relating to haematological features and to phenotypes in other organ systems 
and underwent high throughput sequencing.18 Candidate genes for BPD were 
identified by similarity regression in which ‘baseline’ and ‘alternate’ statistical models 
are compared for every gene.19 Under the baseline model, all cases are assumed to 
have the same log odds of carrying a rare variant. Under the alternate model, which 
we give a prior probability of 0.05 of being the true model, the log odds is modelled as 
a linear function of the phenotypic similarity of each case to an HPO-encoded 
“characteristic phenotype”. The characteristic phenotype (φ) and a binary variable 
indicating the true model (γ) are inferred from the genotype and phenotype data. A 
high posterior mean for γ is indicative of a potential association between the presence 
of a rare variant in a gene and a disorder characterised by φ. The histogram indicates 
the mean posterior probability of the alternate model being true for all 1,073 genes in 
which at least two BPD cases carry a high-impact variant. The value for DIAPH1 is 
indicated in red. (b) The inferred HPO-coded characteristic phenotype (φ) for DIAPH1 
is represented as a graph. Each edge denotes an is-a relationship and each node 
contains an abbreviated HPO term with its marginal posterior probability of inclusion in 
φ, which is also represented by the node size. If a node and all its descendants in the 
HPO graph have a marginal posterior probability of inclusion in φ less than 0.02, it is 
not shown (BBFT: Abnormality of blood and blood forming tissues; TCP: 
Thrombocytopenia; FAIE: Functional abnormality of the inner ear; SNHI: 
Sensorineural hearing impairment. Some terms have been shortened for 
conciseness). (c) Pedigrees of the index cases (*) in which the coloured symbols 
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indicate macrothrombocytopenia (black) and hearing loss (red).  The grey symbols 
indicate that the clinical phenotype is unknown and the white symbols indicate no 
macrothrombocytopenia or hearing loss. Genotyped cases are indicated by +/M for 
the heterozygous DIAPH1 R1213* variant and +/+ for the reference sequence at that 
locus.  
 
Figure 2: Location of the DIAPH1 R1213* variant:  
Schematic representation of the major MK DIAPH1 transcript ENST00000398557 
which is predicted to encode the 1272 amino acid DIAPH1 protein. R1213 is 60 
amino acids from the carboxyl terminus of DIAPH1 within the diaphanous 
autoregulatory domain (DAD). In the amino acid sequence line up of human DIAPH1 
and orthologues, there is conservation of the core MDxLLExL (blue box) and basic 
RRKR (green box) motifs within the DAD that mediate auto-inhibitory interactions 
with the diaphanous inhibitory domain (DID) near the amino terminus of DIAPH1. 
Since R1213 is at position 1 of the basic RRKR motif, R1213* is predicted to cause 
expression of a truncated DIAPH1 protein with an intact core MDxLLExL motif, but 
without the basic RRKR motif. 
 
Figure 3: Effect of R1213* variant on platelet morphology:  
 
Illustration of the typical platelet morphology for cases 10, 16, 17, 21 on a May-
Grünwald-Giemsa (MGG) stained blood smear for case 21 (A) and by TEM (B). 
Plaetlets of control (C) are discoid, of regular size with homogeneously distributed 
granules. All examined platelets of the patients show a heterogeneous size, shape, 
and distribution of α-granules. (A) Arrows highlight platelets (case 21) of different 
size colored by MGG. (B) TEM revealed an abnormal large granule (LG). In the 
31 
 
middle panel a very thin elongated platelet can be seen, other platelets with a more 
round shape have few granules. In the lower panel a very round platelet with many 
granules is illustrated (case 17) the other platelets from case 16 show an abnormal 
presence of vacuoles (V) and a membrane complex (MC) case 17. Scale bars, 1 µm. 
The TEM images were acquired using either an EM900 (Carl Zeiss) or a JEM-1010 
(JEOL) transmission electron microscope. 
 
Figure 4: Repeated megakaryocyte proliferation, differentiation and 
proplatelet-formation studies for a R1213* variant case: (a) Total amount of 
CFU-MK colonies derived from peripheral blood CD34+ mononuclear cells from a 
control (C) and case 21 (21) at day 12 of culture. This experiment was repeated at 
two independent occasions (Exp 1 and Exp 2). (b) Representative images of 
cultured CFU-MK colonies from a control (C) and case 21 (21) at day 12 of culture 
visualised by light microscopy after staining with May-Grünwald-Giemsa (Exp 2). 
Scale bars, 50 μm. (c) MK in suspension triplicated liquid cultures performed at two 
independent occasions were classified as proplatelet forming (PPF-MK) if proplatelet 
extensions were visible by light microscopy. The proportion of PPF-MK was lower in 
the cultures from case 21 compared to controls (One way Anova; ***P>0.001). (d) 
Representative light microscopy images of cultured MK showing formation of 
proplatelet extensions for the control. PPF MKs are almost absent for the case 21 
while they typically present in MK clusters that contain large and small cells. Scale 
bars, 20 µm. (e) Immunofluorescence confocal microcopy images of differentiated 
fibrinogen-adhered MK at day 12 of culture visualised by anti-integrin β3 (green, 
CD61) and phalloidin (red, F-actin) staining, showing co-localisation in MKs from 
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control but not from case 21. Scale bars 20 μm. Numerous PPF MKs are present in 
the control (representative image) while MKs for case 21 form clusters.  
 
Figure 5: Altered expression of DIAPH1-3 and cytoskeletal organisation in 
platelets from R1213* variant cases: (a) Representative Western blots of resolved 
platelet protein extracts from R1213* cases (10 and 16) and from control (C), probed 
with antibodies recognising DIAPH1, DIAPH2, DIAPH3 and GAPDH. Compared with 
the control, the R1213* cases, show reduced intensity of the 155 kDa anti-DIAPH1 
immunoreactive band corresponding to full length wild type DIAPH1, but markedly 
increased intensity of an 80 kDa band, shown by mass spectrometry to contain 
peptides corresponding to DIAPH1. It was not possible to resolve the relative 
contributions of wild type and R1213* DIAPH1 to either of these bands. The content 
of DIAPH2 and DIAPH3 is increased in the cases compared to control. Similar 
quantities of total protein in the Western blot lanes are indicated by the control blot 
probed with an antibody recognising GAPDH. (b) Confocal microscopy images of 
poly-L-lysine-immobilised, resting platelets from the cases 10 and 16 and from a 
control (C), stained for DIAPH1 (cyan), F-actin (red) and α-tubulin (green). DIAPH1 is 
abnormally distributed throughout the cytoplasm of platelets from the cases. There is 
an increased F-actin content and number of microtubules with an abnormal 
distribution in platelets from the cases. Platelets were visualised using a Leica TCS 
SP5 confocal microscope (Leica Microsystems). Scale bars, 3 μm. (c) 
Representative transmission electron micrographs showing that the microtubules 
(MT; arrowed) are disorganised and distributed throughout the cytoplasm of platelets 
from case 10 compared to controls in which microtubules are organised into the 
marginal band. Images were collected using a EM900 (Carl Zeiss) electron 
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microscope. Scale bar, 0.5 μm. (d) Manual counting of microtubules revealed an 
increased number of microtubules in platelets from the cases (n=41 platelets) 
compared with controls (n=104 platelets). Microtubule numbers per platelet are 
expressed as mean ± s.d. *** indicates P < 0.001 by unpaired Student’s t-test.  
 
Figure 6:  Increased microtubule stability in platelets from R1213* cases: (a 
and b) Representative confocal microscopy images of platelets from R1213* cases 
(10 and 16) and from a control (C) after incubation at 4°C and after subsequent re-
warming to 37°C (a) or after treatment with the microtubule destabilising toxin 
colchicine (b). F-actin (F-act) is displayed as red and post-translationally modified α-
tubulin (ac-tub and Glu-tub) as green. (c) Confocal microscopy images of platelets 
after spreading on fibrinogen (100 µg µL-1). F-act is displayed as red and α-tub, ac-
tub or Glu-tub as green. Platelets were visualised using a Leica TCS SP5 confocal 
microscope (Leica Microsystems). Scale bars, 3μm. (d) Western blots of the platelet 
microtubule cytoskeleton in total protein extract (T) or in pellet (P) or soluble (S) 
fractions separated by ultracentrifugation, probed with antibodies recognising Tyr-
tub, ac-tub or Glu-tub. Data are presented from resting platelets (rest) and after 
treatment with 10 µM colchicine (colch). (C= healthy control; 10= case 10 and 16= 
case 16). Equivalent quantities of total platelet extract protein were loaded in each 
lane.  
  
Figure 7: Overexpression of DIAPH1 R1213* in cell lines reproduces the 
cytoskeletal alterations in platelets: (a) Western blot of protein extracts from 
HEK293FT cells transfected with DIAPH1 wild-type (WT), DIAPH1 R1213* (R1213*) 
or empty (C) expression constructs, probed with antibodies recognising the DIAPH1 
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amino terminus, DIAPH2 or DIAPH3. (b-d) Confocal microscopy images of A549 
cells transiently transfected with the DIAPH1 R1213* expression construct were 
stained for DIAPH1 (cyan), F-actin (red) and α-tubulin or acetylated-tubulin (ac-
tubulin; green) and with DAPI nuclear counterstain (blue). There was an increased 
content of F-actin, α-tubulin and ac-tubulin in the cells overexpressing DIAPH1 
R1213* compared with adjacent non-transfected cells (b, c). Incubation with the 
FH2 domain inhibitor SMIFH2 reduced F-actin content, but not the content of ac-
tubulin (d). The cells were visualised using a Leica TCS SP5 confocal microscope 
(Leica Microsystems). Scale bars, 10 µm. (e) Western blots of the microtubule 
cytoskeleton in total protein extract (T) and in pellet (P) or soluble (S) tubulin 
fractions separated by ultracentrifugation of the transfected cells, probed with 
antibodies recognising Tyr-tubulin, ac-tubulin or Glu-tubulin. Incubation with SMIFH2 
did not influence the post-translational modification of tubulin, confirming that the 
DIAPH1 FH2 domain is not critical for the stabilization of microtubules. For the 
Western blots, there were equivalent total quantities of protein in the cell extracts in 
each lane confirmed by probing with an antibody recognising β-tubulin 
(Supplementary Fig. 12 and 13). 
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Pedigree 1 2 
Case 10 14 15 16 17 21 22 24 
Gender M F M F F F M M 
Year of birth in 5-year 
bins 
 
1951-55 
 
1976-80 
 
1976-80 
 
1981-85 
 
1976-80 
 
1976-80 
 
2001-05 
 
2006-10 
Platelet count 
(x109 L-1; N: 150-400) 
 
69-110 
 
97 
 
140-147 
 
66-114 
 
94-107 
 
63-115 
 
116-129 
 
93 
Mean platelet volume 
(fL; N: 7-9) 
 
13.6 
 
11.2 
 
13.5 
 
13.1-14.1 
 
12.1 
 
13.2 
 
nk 
 
nk 
Neutrophil count 
(x109 L-1; N: 2-7.5) 
 
1.21 
 
1.49 
 
1.66 
 
3.11-3.74 
 
0.9-2.27 
 
1.29-4.34 
 
0.64-1.84 
 
0.62-1.02 
Haemoglobin 
(g dL-1; N: 12-15) 
 
13.2-14.1 
 
12.7 
 
15 
 
12.3-12.5 
 
10.9-12.4 
 
10.2-12.6 
 
11.2-11.8 
 
10.4-10.8 
Bleeding score† 
(<4) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Type of hearing loss  
SN 
 
SN 
 
SN, C 
 
SN 
 
SN 
 
SN 
 
SN 
 
SN 
Age of hearing loss 
(years) 
 
8 
 
2 
 
8 
 
6 
 
6 
 
nk 
 
2 
 
1 
Table 1: Characteristics of eight cases with the DIAPH 1 R1213* variant. † bleeding score determined using the International Society of 
Thrombosis and Haemostasis Bleeding Assessment Tool. Pathological bleeding is associated with bleeding scores >4. NK-not known; SN- 
sensorineural; C- conductive. 
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Table 2. Quantitative morphometric evaluation of platelet size parameters for patients and controls usingelectron microscopy 
*n corresponds to the number of platelet sections examined. Data were analyzed for morphometrics parameters.  
 
 
 
 
 
Groups (n)* 
 
Area [µm2] 
 
Maximal diameter [µm] 
 
Minimal diameter [µm] 
 
% platelets > 4 µm2 
 
Control (862) 
 
2.53 ± 1.47 
 
2.89 ± 0.67 
 
1.09 ± 0.46 
 
10.90 
 
P10 (99) 
 
3.90 ± 2.50 
 
3.17 ± 0.76 
 
1.51 ± 0.73 
 
31.26 
 
P16 (107) 
 
6.84 ± 4.92 
 
3.77 ± 0.96 
 
2.14 ± 0.91 
 
71.03 
 
P17 (100) 
 
5.48 ± 3.30 
 
3.64 ± 0.90 
 
1.85 ± 0.81 
 
49.00 
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